The LiBBY trial found that a specific twice-daily THC-plus-CBD oil lowered agitation in hospice-eligible people with late-stage dementia. Spouses and partners should not read that result as a reason to try cannabis products at home.
LiBBY stands for Life's End Benefits of cannabidiol and tetrahydrocannabinol. Here agitation means restlessness, shouting, hitting, or resisting care that distresses the person and family. The Alzheimer's Association described the study as a short Phase 2 trial in 120 people receiving end-of-life care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What LiBBY enrolled and gave
- How agitation scores changed
- How to read safety in a frail group
- Why this is not a cannabis prescription
- What spouses and partners can do next
What LiBBY enrolled and gave
The study enrolled hospice-eligible adults with Alzheimer's or other dementia plus agitation. Care took place in homes or residences through 10 United States centers. Jacobo Mintzer and Brigid Reynolds led the research.
Participants on treatment received a proprietary oral oil with 2 mg THC plus 100 mg CBD twice daily versus placebo, according to Georgetown University School of Medicine in its trial summary. The oil was purified and dosed for the trial. It was not a dispensary product.
How agitation scores changed
CMAI means Cohen-Mansfield Agitation Inventory, a scale that rates agitation behaviors. Psychiatric Times reported rapid separation at week 2, with about 6.27 points greater reduction than placebo in its July 16 report. Scores fell 10.61 points on treatment versus 4.35 points on placebo.
Benefit lasted to week 12 with about 8.23 points greater CMAI reduction than placebo, according to Pennington Biomedical Research Center in its July 28 summary. Clinician-rated global improvement reached 87.2 percent on treatment versus 23.6 percent on placebo. At week 2, the rates were 83.9 percent versus 30.5 percent.
How to read safety in a frail group
Overall adverse events were similar, 46.7 percent on treatment versus 42.4 percent on placebo, mainly infections and stomach or bowel issues. Serious adverse events were higher with treatment, 23.3 percent versus 11.9 percent. Investigators judged those serious events unrelated to study drug.
High illness rates are expected in hospice-eligible late-stage dementia. A similar overall rate does not mean low risk. Families should report fever, vomiting, diarrhea, falls, new confusion, or reduced eating to the hospice team right away.
Why this is not a cannabis prescription
The findings apply only to this hospice-eligible, late-stage population and to MediPharm Labs' specific purified oil, dose, and formulation, according to the LiBBY Study team in its results summary. They do not apply to dispensary cannabis, edibles, smoked products, or early-stage agitation. Dose, purity, and daily THC exposure differ widely outside a trial.
A trial oil that helps under close visits can still harm without that structure. Home products lack the same checks, staff review, and follow-up. Do not borrow, buy, or adjust a cannabis oil to copy the study dose.
What spouses and partners can do next
Track what the hospice team needs to judge agitation. Note the behavior, time of day, pain, hunger, thirst, toilet needs, sleep, visitors, and what helped.
Share medicines, supplements, alcohol, and recent infections or falls. Bring that one-page note to the next hospice visit.
- Write one page: main behaviors, triggers, sleep, pain, and recent changes
- Ask about medical causes: infection, dehydration, constipation, pain, or drug effects
- Ask about care steps: routine, noise, light, bathing approach, and respite support
- Ask what agitation treatments the hospice plan allows
- Do not start cannabis at home while waiting for answers
You Might Also Like
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: How Spouses and Partners Can Avoid Overreading the Headline
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: How Spouses and Partners Can Avoid Overreading the Headline
- The Ideal Dementia Care Map Discussed by NIA in 2026: What Changed and What Comes Next for Spouses and Partners





